Adam Khader1, Weng-Lang Yang2, Laura W Hansen3, Salil R Rajayer4, Jose M Prince5, Jeffrey M Nicastro3, Gene F Coppa3, Ping Wang6. 1. Elmezzi Graduate School of Molecular Medicine, Manhasset, New York; Department of Surgery, Hofstra Northwell School of Medicine, Hempstead, New York. 2. Elmezzi Graduate School of Molecular Medicine, Manhasset, New York; Department of Surgery, Hofstra Northwell School of Medicine, Hempstead, New York; Center for Immunology and Inflammation, The Feinstein Institute for Medical Research, Manhasset, New York. 3. Department of Surgery, Hofstra Northwell School of Medicine, Hempstead, New York. 4. Center for Immunology and Inflammation, The Feinstein Institute for Medical Research, Manhasset, New York. 5. Department of Surgery, Hofstra Northwell School of Medicine, Hempstead, New York; Center for Immunology and Inflammation, The Feinstein Institute for Medical Research, Manhasset, New York. 6. Elmezzi Graduate School of Molecular Medicine, Manhasset, New York; Department of Surgery, Hofstra Northwell School of Medicine, Hempstead, New York; Center for Immunology and Inflammation, The Feinstein Institute for Medical Research, Manhasset, New York. Electronic address: pwang@northwell.edu.
Abstract
BACKGROUND: Sepsis affects 800,000 patients in the United States annually with a mortality rate of up to 30%. Recent studies suggest that sepsis-associated metabolic derangements due to hypoxic tissue injury, impaired oxygen utilization, and mitochondrial dysfunction contribute to mortality. Sirtuin 1 (Sirt1) is a crucial modulator of energy metabolism during starvation states and has anti-inflammatory effects. Here, we hypothesized that SRT1720, a Sirt1 activator, could attenuate the severity of sepsis. MATERIALS AND METHODS: Male C57BL/6 mice (20-25 g) were subjected to cecal ligation and puncture (CLP) to induce sepsis. SRT1720 (5 or 20 mg/kg BW) or 10% dimethyl sulfoxide (vehicle) in 0.2-mL saline was injected intravenously at 5 h after CLP. Control animals were not subjected to any surgery. Blood and liver samples were harvested at 20 h after CLP for analysis. RESULTS: Administration of SRT1720 markedly reduced the serum levels of tissue injury markers (aspartate aminotransferase, alanine aminotransferase, and lactate dehydrogenase) and renal injury markers (blood urea nitrogen and creatinine) in a dose-dependent manner after CLP. Furthermore, the levels of proinflammatory cytokines interleukin (IL)-1β and IL-6 in the serum and liver were significantly inhibited by SRT1720 treatment after CLP. SRT1720 treatment resulted in a significantly decreased mRNA expression of inflammasome components (nucleotide oligomerization domain-like receptor protein 3, adapter apoptosis-associated speck-like protein containing caspase-recruitment domain, IL-1β, and IL-18) in the liver, compared with the vehicle group. CONCLUSIONS: SRT1720 treatment attenuates multiorgan injury in septic mice. SRT1720 treatment also decreases the production of proinflammatory cytokines and reduces inflammasome activation. Thus, pharmacologic stimulation of Sirt1 may present a promising therapeutic strategy for sepsis.
BACKGROUND:Sepsis affects 800,000 patients in the United States annually with a mortality rate of up to 30%. Recent studies suggest that sepsis-associated metabolic derangements due to hypoxic tissue injury, impaired oxygen utilization, and mitochondrial dysfunction contribute to mortality. Sirtuin 1 (Sirt1) is a crucial modulator of energy metabolism during starvation states and has anti-inflammatory effects. Here, we hypothesized that SRT1720, a Sirt1 activator, could attenuate the severity of sepsis. MATERIALS AND METHODS: Male C57BL/6 mice (20-25 g) were subjected to cecal ligation and puncture (CLP) to induce sepsis. SRT1720 (5 or 20 mg/kg BW) or 10% dimethyl sulfoxide (vehicle) in 0.2-mL saline was injected intravenously at 5 h after CLP. Control animals were not subjected to any surgery. Blood and liver samples were harvested at 20 h after CLP for analysis. RESULTS: Administration of SRT1720 markedly reduced the serum levels of tissue injury markers (aspartate aminotransferase, alanine aminotransferase, and lactate dehydrogenase) and renal injury markers (blood ureanitrogen and creatinine) in a dose-dependent manner after CLP. Furthermore, the levels of proinflammatory cytokines interleukin (IL)-1β and IL-6 in the serum and liver were significantly inhibited by SRT1720 treatment after CLP. SRT1720 treatment resulted in a significantly decreased mRNA expression of inflammasome components (nucleotide oligomerization domain-like receptor protein 3, adapter apoptosis-associated speck-like protein containing caspase-recruitment domain, IL-1β, and IL-18) in the liver, compared with the vehicle group. CONCLUSIONS: SRT1720 treatment attenuates multiorgan injury in septic mice. SRT1720 treatment also decreases the production of proinflammatory cytokines and reduces inflammasome activation. Thus, pharmacologic stimulation of Sirt1 may present a promising therapeutic strategy for sepsis.
Authors: Arun Baksi; Oleg Kraydashenko; Alsu Zalevkaya; Roman Stets; Peter Elliott; Jonathan Haddad; Ethan Hoffmann; George P Vlasuk; Eric W Jacobson Journal: Br J Clin Pharmacol Date: 2014-07 Impact factor: 4.335
Authors: Li Diao; Alexandra H Marshall; Xiaojing Dai; Elena Bogdanovic; Abdikarim Abdullahi; Saeid Amini-Nik; Marc G Jeschke Journal: Shock Date: 2014-02 Impact factor: 3.454
Authors: Adam Khader; Weng-Lang Yang; Michael Kuncewitch; Asha Jacob; Jose M Prince; Jaya R Asirvatham; Jeffrey Nicastro; Gene F Coppa; Ping Wang Journal: Transplantation Date: 2014-07-27 Impact factor: 4.939
Authors: Joanne M Ajmo; Xiaomei Liang; Christopher Q Rogers; Brandi Pennock; Min You Journal: Am J Physiol Gastrointest Liver Physiol Date: 2008-08-28 Impact factor: 4.052
Authors: Steven M Opal; Pierre-Francois Laterre; Bruno Francois; Steven P LaRosa; Derek C Angus; Jean-Paul Mira; Xavier Wittebole; Thierry Dugernier; Dominique Perrotin; Mark Tidswell; Luis Jauregui; Kenneth Krell; Jan Pachl; Takeshi Takahashi; Claus Peckelsen; Edward Cordasco; Chia-Sheng Chang; Sandra Oeyen; Naoki Aikawa; Tatsuya Maruyama; Roland Schein; Andre C Kalil; Marc Van Nuffelen; Melvyn Lynn; Daniel P Rossignol; Jogadish Gogate; Mary B Roberts; Janice L Wheeler; Jean-Louis Vincent Journal: JAMA Date: 2013-03-20 Impact factor: 56.272